Summary: A two-year multidomain lifestyle intervention reduced cognitive decline even among people who carry the APOE ε4 gene, a known genetic risk factor for Alzheimer’s disease, according to new analysis of the FINGER randomized trial.
Source: University of Eastern Finland
Enhanced lifestyle counselling prevents cognitive decline even in APOE ε4 carriers, a new JAMA Neurology analysis reports.
Researchers analyzing data from the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) found that an intensive lifestyle program—combining diet, physical activity, cognitive training, and vascular risk management—helped maintain cognitive function in older adults at risk for dementia, regardless of whether they carried the APOE ε4 allele. The results were published in JAMA Neurology and strengthen evidence that early, multidomain prevention strategies can benefit cognition for at-risk populations.
The FINGER trial enrolled community-dwelling adults aged 60–77 who had elevated risk for cognitive decline based on cardiovascular and lifestyle factors. Participants were randomly assigned to either an active intervention group that received enhanced lifestyle counselling and structured support, or to a control group that received regular health advice. The enhanced program provided personalized nutritional counselling, guided physical exercise, structured cognitive training exercises, and clinical management to control vascular risk factors such as hypertension and cholesterol.
The subgroup analysis examined whether APOE ε4 status modified the cognitive benefits of the intervention. APOE ε4 is the strongest common genetic risk factor for late-onset Alzheimer’s disease, and some have feared that genetic susceptibility could limit the effectiveness of lifestyle interventions. In this analysis, genotype data were available for 1,109 participants, of whom 362 were APOE ε4 carriers and 747 were noncarriers.
Baseline characteristics were broadly similar between carriers and noncarriers except for expected differences in serum cholesterol. Cognitive outcomes were measured by a comprehensive neuropsychological test battery and analyzed using a modified intention-to-treat approach, including participants with at least one post-baseline assessment. The primary outcome focused on change in global cognitive performance over the two-year intervention period.
Results showed that the enhanced, multidomain intervention produced cognitive benefits regardless of APOE ε4 carrier status. Among APOE ε4 carriers, the annual change in the neuropsychological test battery total score favored the intervention group. Carriers in the intervention arm experienced a greater reduction in cognitive decline compared with carriers in the control arm. Noncarriers also benefited, and the difference in intervention effect between carriers and noncarriers was not statistically significant, indicating the intervention’s positive effect applied across genetic subgroups.
Lead author Adjunct Professor Alina Solomon noted that many people worry genetic risk could undermine lifestyle interventions, but the FINGER findings are reassuring: “We were very happy to see that genetic risk did not prevent benefits from the intensive, early intervention implemented in our trial.” Principal investigator Professor Miia Kivipelto emphasized the broader impact: “The FINGER intervention model is now being adapted and tested globally through the World Wide FINGERS initiative. Trials in diverse populations will help refine international dementia prevention strategies.”
The study was conducted through a collaboration involving the University of Eastern Finland, the Finnish National Institute for Health and Welfare, the University of Helsinki, the University of Oulu, and Karolinska Institutet. The analysis included 1,109 participants (mean age 69.3 years; 46.3% female), with 173 APOE ε4 carriers assigned to the intervention and 189 carriers assigned to control. Among noncarriers, 380 were in the intervention group and 367 in control. The effect size for annual change in the neuropsychological total score was positive for both carriers and noncarriers, supporting the benefit of multidomain lifestyle modification.
Original research: JAMA Neurology (Abstract available under the study title in journal archives). DOI: 10.1001/jamaneurol.2017.4365
Abstract
Cognitive Change During a Multidomain Lifestyle Intervention: A Subgroup Analysis of a Randomized Clinical Trial
Importance: It has been unclear whether the APOE ε4 allele modifies the cognitive benefits of lifestyle interventions designed to prevent dementia.
Objective: To determine whether APOE ε4 carrier status alters the effect of a two-year multidomain lifestyle intervention on cognition in older adults at risk for cognitive impairment.
Design, Setting, and Participants: The FINGER trial randomized at-risk older adults (age 60–77) across six centers in Finland to a combined intervention or control condition between September 2009 and November 2011, with two years of follow-up. APOE genotype data were available for the majority of participants included in this analysis.
Interventions: The multidomain intervention included tailored nutritional guidance, structured physical exercise, cognitive training, and management of vascular risk factors. The control group received general health advice.
Main Outcomes and Measures: Primary outcome was change in a comprehensive neuropsychological test battery total score. Analysis used a modified intention-to-treat sample including participants with at least one post-baseline assessment.
Results: Among 1,109 participants analyzed, 362 were APOE ε4 carriers and 747 were noncarriers. Both carriers and noncarriers showed cognitive benefit from the enhanced intervention compared with control. The intervention effect did not differ significantly between carriers and noncarriers.
Conclusions and Relevance: Multidomain lifestyle changes that combine diet, exercise, cognitive training, and vascular risk management can support cognitive health in older adults at increased risk for dementia, even among those with APOE-related genetic susceptibility. These findings underline the importance of early, comprehensive prevention strategies targeting multiple modifiable risk factors simultaneously.